Here, I share my expertise in international market development, licensing negotiations, and global trade shows, alongside the intriguing cross-cultural experiences.
$2.1B for a drug with zero efficacy data. $7B for another. In vivo CAR-T isn't a science story — it's a business model story.
CAR-T proved that engineered immune cells can transform cancer treatment. But most cancer targets remain hidden inside the cell—beyond CAR-T’s reach. Could TCR-T unlock these targets and become the next major platform for treating solid tumors?
CAR-T has changed cancer treatment—but it is also exposing the limits of today's healthcare payment systems. Why can a therapy be cost-effective yet still threaten insurance budgets? Explore how CAR-T is reshaping reimbursement, health economics, and the future of Cell & Gene Therapy.
CAR-T has transformed cancer treatment, but its One Patient, One Batch model limits scalability. Can allogeneic CAR-T overcome manufacturing scalability bottlenecks and redefine the future of cell therapy?
Manufacturing makes CAR-T possible. Hospitals make CAR-T scalable. CAR-T's biggest commercialization challenge isn't manufacturing alone. Hospital capacity—from patient selection and leukapheresis to CRS management and reimbursement—may be the real bottleneck limiting market expansion.
CAR-T therapy has delivered remarkable clinical outcomes, yet scaling manufacturing remains one of the industry's greatest challenges. Learn why CAR-T isn't simply selling engineered cells—it's selling an entire vein-to-vein supply chain
CAR-T therapy transformed cancer treatment, but scientific breakthroughs alone don't guarantee commercial success. Discover why manufacturing, supply chains, hospital capacity, and reimbursement became the real bottlenecks behind CAR-T commercialization.
In Asian business, alcohol is not just a drink, it serves as a medium to "lower the social barrier." It allows people from professional roles to true character, and it's often the key to move a partnership beyond contract to trust.
In the world of Business Development (BD), I’ve observed a fascinating difference between the "Western" and "Taiwanese" approach: Is it better to aim first, or fire immediately?
